XORTX Therapeutics Inc. welcomed Mr. Patrick Treanor to the Board of Directors and announced the resignation of Ian Klassen, both effective December 31, 2023. Mr. Treanor is a seasoned pharmaceutical industry executive. He is the current Chief Operating Officer of Pathalys Pharma Inc., a private company focused on the development of advanced therapeutics to improve the management of late stage chronic kidney disease.

He previously served as President, US for Vifor Pharma, an international pharmaceutical company focused on nephrology. Mr. Treanor began his career with large pharmaceutical organizations such as Johnson & Johnson and Abbott Laboratories over 25 years ago but found his niche building early-stage commercial organizations at companies such as Oscient Pharmaceuticals, AMAG Pharmaceuticals, Insulet Corporation and Relypsa Pharmaceuticals. Mr. Treanor currently serves on the board of directors of KalVista Pharmaceuticals Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors.

He holds a BS in Management from Bryant University and an MBA from Rensselaer Polytechnic Institute.